No biomarkers for antidepressant efficacy in major depressive disorder (MDD) are available
that can reduce patient suffering and healthcare costs from ineffective trials. This dissertation …

Introduction Pretreatment positron emission tomography (PET) with 2-deoxy-2-[18 F] fluoro-
D-glucose (FDG) and magnetic resonance spectroscopy (MRS) may identify biomarkers for …

There is a critical need to identify objective predictive markers of treatment response in
major depressive disorder (MDD), given the high levels of illness morbidity and the fact that …

The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more.
Treatment of patients with MDD without predictors of treatment response and future …

Many previous intervention studies have used functional magnetic resonance imaging
(fMRI) data to predict the antidepressant response of patients with major depressive disorder …

Background Current practice for selecting pharmacological and non-pharmacological
antidepressant treatments has yielded low response and remission rates in Major …

Background Due to the biological heterogeneity, 60%–70% of patients with major
depressive disorder (MDD) do not respond to or achieve remission from first‐line …

Depressive disorders are highly heterogeneous in nature. Previous studies have not been
useful for the clinical diagnosis and prediction of outcomes of major depressive disorder …

Diagnosis of depression is based on clinical parameters which may be clinically reliable but
lack biological validity leading to problems of differential diagnosis or treatment. Thus, there …

Abstract Purpose of Review This paper aims to review the findings on neuroimaging as a
tool for facilitating individualized treatment choice in depression. Recent Findings …